Search Results - covid-19

55 Results Sort By:
Combination Therapy to Treat Viral Acute Respiratory Distress Syndrome (ARDS)
­Advantages: PG’s anti-inflammatory effects mitigate viral inflammation of COVID-19. Intranasally administered mesenchymal stem cells (MSCs) create an anti-inflammatory microenvironment and can enhance neuro-regenerative effects. Targets viral transmission and neuronal damage to reduce virus-induced neuronal damage, and mortality, and...
Published: 7/15/2024   |   Inventor(s): Subhra Mohapatra, Shyam Mohapatra, Mahasweta Das, Andrew McGill, Karthick Mayilsamy
Keywords(s): Covid-19, Respiratory Diseases Treatment
Category(s): Technology Classifications > Medical > Respiratory
Low-Cost, Point-of-Care Test for Rapid Visual Diagnosis of COVID-19
A rapid, low-cost, portable swab-based SARS-CoV-2 biosensor whose test result can be detected with naked eye Problem: COVID-19 has killed over 2.84 million people worldwide and has disproportionately affected people in lower-income and resource-limited geographies. High-frequency testing can prevent rapid virus spread and reduce COVID-19-related hospitalizations...
Published: 6/26/2024   |   Inventor(s): Cesar de la Fuente-Nunez, Marcelo Der Torossian Torres, Lucas Felipe de Lima, Andre Lopes Ferreira
Keywords(s): Bioengineering, COVID-19, Infectious Disease
Category(s): Technology Classifications > Diagnostics, Technology Classifications > Medical Devices
Targeted Lentiviral Transduction of B-Cells With Desired B-Cell Receptor Specificity (UCLA Case No. 2023-237)
UCLA researchers in the Division of Hematology and Oncology in the Department of Medicine, have discovered novel lentiviral vectors that can be used for gene delivery to B-cells and for the development of neutralizing antibodies against viruses. BACKGROUND: Microbial tropism is a microbiology term that describes the types of animals (including human),...
Published: 3/15/2024   |   Inventor(s): Kouki Morizono
Keywords(s): B Cell, cell receptor, COVID-19, VIral entry, Virus
Category(s): Therapeutics > Immunology And Immunotherapy
­IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS
­IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS Researchers at Stanford have developed fusion proteins as a novel vaccine strategy for SARS-CoV2. As the causative force of the COVID-19 pandemic, SARS-CoV2 caused massive sustained morbidity, mortality, and societal disruption worldwide. Though COVID-19 has largely transitioned from...
Published: 10/6/2023   |   Inventor(s): Peter Kim, Natalia Friedland, Mrinmoy Sanyal, Payton Weidenbacher
Keywords(s): Coronavirus, COVID, COVID-19, Infectious Disease, Vaccine
Category(s): Technology Classifications > Biology
Tempol as a Therapeutic to Treat Covid-19 Via Inhibition of Viral Replication
Abstract: Despite several partially effective prophylactic vaccines for SARS-CoV-2 exist, patients worldwide still succumb to COVID-19. New therapeutics to treat this disease are still needed.  Upon host invasion, a critical step in the pathogenesis of COVID-19 is intracellular replication of SARS-CoV-2 before viral particles invade nearby healthy cells....
Published: 4/8/2024   |   Inventor(s): Tracey Rouault, William Linehan, Nunziata Maio
Keywords(s): ANTIVIRAL, COVID-19, RdRP Inhibitor, RNA-dependent RNA Polymerase inhibitor, Rouault, SARS-CoV-2, Tempol
Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology
RNASEH-Assisted Detection Assay for RNA
Abstract: Several viral epidemics – such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 – have profoundly impacted global human health. Early identification of infected and/or infectious...
Published: 8/14/2024   |   Inventor(s): G Esta Sterneck, Dipak Poria
Keywords(s): COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA
Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration
Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method
Abstract: DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab...
Published: 4/8/2024   |   Inventor(s): Bin Guan, Robert Hufnagel
Keywords(s): Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus
Category(s): TherapeuticArea > Oncology, Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
Therapeutics Against Pathogenic Coronaviruses
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available...
Published: 4/8/2024   |   Inventor(s): Melvin DePamphilis, Matthew Frieman, Arup Chakraborty
Keywords(s): CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...
Published: 7/29/2024   |   Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan
Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Jessica Hong
Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein
Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics
1 2 3 4 5 6